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Introduction: Arsenic exposure is a significant cause of lung cancer 
in North America and worldwide. Arsenic-related tumors are struc-
turally indistinguishable from those induced by other carcinogens. 
Because carcinogens, like tobacco, induce distinctive mutational 
signatures, we sought to characterize the mutational signature of 
an arsenic-related lung tumor from a never smoker with the use of 
whole-genome sequencing.
Methods: Tumor and lung tissues were obtained from a never 
smoker with lung squamous cell carcinoma (LUSC), without famil-
iar history of lung cancer and chronically exposed to high levels of 
arsenic-contaminated drinking water. The Illumina HiSeq-2000 plat-
form was used to sequence each genome at approximately 30-fold 
haploid coverage. The mutational signature was compared with those 
observed in previously characterized lung tumors.
Results: The arsenic-related tumor exhibited alterations common in 
LUSC, such as the increased number of copies at 3q26 (SOX2 locus). 
However, the arsenic-related genome not only harbored a lower num-
ber of point mutations, but also had a remarkably high fraction of 
T>G/A>C mutations and low fraction of C>A/G>T transversions, 
which is uncharacteristic of LUSCs. Furthermore, at the gene level, 
we identified a rare G>C mutation in TP53, which is uncommon in 
lung tumors in general (<0.2%) but has been observed in other arse-
nic-related malignancies.
Conclusions: We generated the first whole-genome sequence of an 
LUSC from a never-smoker patient chronically exposed to arsenic, 
and identified a distinct mutational spectrum associated with arsenic 
exposure, providing novel evidence supporting the hypothesis that 
arsenic-induced lung tumors arise through molecular mechanisms 
that differ from those of the common lung cancer.
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Transversions.
(J Thorac Oncol. 2013;8: 1451–1455)
Arsenic exposure affects more than 150 million people worldwide. Ingestion of arsenic through drinking water 
is related to higher incidences of cancer in various organs, 
including skin, bladder, kidney, liver, and lungs.1 In the United 
States alone, it is believed that chronic, low-level exposure 
to arsenic contributes to as many as 5000 lung cancer cases 
per year.2
Although arsenic-related lung tumors are histologically 
similar to those induced by tobacco smoke and other lung car-
cinogens, important arsenic-specific clinical and molecular 
differences have been reported. For instance, lung squamous-
cell carcinoma (LUSC) is the most frequent subtype affect-
ing never smokers chronically exposed to arsenic.3 Molecular 
characteristics associated with arsenic-related tumors in mul-
tiple organs have been reported, including weak mutagenic-
ity and distinct DNA copy-number alterations.3,4 An improved 
understanding of the molecular biology underlying arsenic-
related malignancies is critical to rational development of pre-
vention, monitoring, and treatment strategies.
Whole-genome sequencing (WGS) of human tumors 
has enabled identification of distinctive mutational signa-
tures associated with specific carcinogens, and has provided 
much insight into cancer origin. Such analyses in arsenic-
related tumors are difficult because of the rarity of fresh fro-
zen samples and challenges in the confirmation of chronic 
arsenic exposure. In this report, we provide the first WGS 
analysis of an arsenic-related LUSC (As-LUSC) and paired 
lung normal tissue sample from a chronically exposed, 
never-smoker patient.
PATIENTS AND METHODS
Patient Sample
A 71-year-old female patient with no history of ciga-
rette smoking, with clinical signs of arsenicosis, was diag-
nosed with LUSC in 2012. The patient resided in Antofagasta, 
Northern Chile, for 50 years before cancer diagnosis. In this 
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region, arsenic levels in drinking water averaged 870 μg/liter 
during 1956–1970, and gradually decreased to 40 μg/liter by 
1994, which is still four times the current acceptable level 
of 10 µg/liter.5 Tissue collection and analysis were approved 
by the Ethics Committee Board of the Faculty of Medicine, 
University of Chile, Chile (case ID: 085-2008). Histological 
examination confirmed LUSC diagnosis (Fig. 1A) and also 
exhibited features consistent with LUSC, such as amplifica-
tion at 3q26 correlated with SOX2 overexpression.
Genome Sequencing and Analysis
Paired-end WGS was performed for tumor and non-
malignant tissues with the use of the Illumina HiSeq-2000 
platform at the Beijing Genomic Institute (China). A mini-
mum of ×30 haploid coverage was generated for each sample. 
Sequences were aligned to the human genome build 37 (hg19) 
and deposited in a public repository (BioSample accession: 
SAMN02356008). Genomic variants were identified as previ-
ously described.6 Somatic mutations were called by compar-
ing reads from tumor and normal samples.7 Somatic mutations 
affecting coding DNA sequences (CDSs) were selected for 
further studies.
External Data
A total of 171 LUSCs (164 smokers and 7 never smok-
ers) were downloaded from The Cancer Genome Atlas Data 
Portal (https://tcga-data.nci.nih.gov/tcga/).
RESULTS
As-LUSC Exhibits Low Mutational Load 
Compared with Other Lung Tumors
Somatic single-nucleotide variants analyses revealed 
only 49 nonsynonymous mutations affecting CDSs (Fig. 1B). 
The CDS mutational load is low compared with that observed 
in 171 tumors of the same histological type (Fig. 2A). This 
pattern of low mutational load holds true even when compared 
with seven LUSC tumors from never smokers, which would 
not have accumulated tobacco-induced mutations—as never-
smoker tumors are known to harbor fewer single-nucleotide 
variants than tumors from smokers (Fig. 2B).8
Mutational Landscape of As-LUSC
Because lung tumors of different types and with differ-
ent smoking histories are characterized by distinct mutational 
FIGURE 1.  Lung squamous-cell 
carcinoma from an arsenic-exposed 
patient. A, Hemotoxylin and eosin 
stained section is shown at ×200 
magnification. B, Total number of 
mutations (in blue) and those affect-
ing CDSs (in red) are shown. In both 
cases, the highest number of muta-
tions were C>T/G>A transitions. In 
CDS regions C>T/G>A and G>C/C>G 
exhibit almost equal numbers of muta-
tions. CDS, coding DNA sequence.
FIGURE 2.  As-LUSC displays a low CDS mutational load: 
Box-and-whisker plots (min/25th percentile/median/75th 
percentiles/max) comparing somatic nonsynonymous muta-
tions affecting CDS in the As-LUSC (49 mutations, red line) 
with 171 LUSC tumors from: lifelong NSs, FSs, and CSs. NS, 
never smoker; FS, former smoker; CS, current smoker; LUSC, 
lung squamous-cell carcinoma; As-LUSC, arsenic-related LUSC; 
CDS, coding DNA sequence; TCGA, The Cancer Genome Atlas.
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spectra, that is, patterns of transitions and transversions, we 
examined the spectra of mutations found in the As-LUSC. 
When we analyzed mutations affecting CDS in this tumor the 
most prominent type of point mutations were C>T/G>A tran-
sitions and G>C/C>G transversions; whereas T>A/A>T and 
C>A/G>T transversions were the least frequent. These pat-
terns hold true when the whole genome (including noncoding 
DNA) is considered (Fig. 1B).
A Distinctive Mutational Spectrum 
Defines As-LUSC Compared with 
Non–Small-Cell Lung Cancer
When compared with other LUSC (Fig. 3A), the 
As-LUSC exhibited a markedly higher fraction of T>G/A>C 
transversions (16.3% in the As-LUSC, compared with 171 
LUSC genomes [median values between 2.4% and 3.9%]). 
The p value for a permutation test comparing these two groups 
FIGURE 3.  As-LUSC displays a 
distinct mutational profile compared 
with other LUSC. A, Mutational 
spectrum of the As-LUSC compared 
with 171 LUSC tumors from TCGA, 
ordered by smoking status. Each ver-
tical column represents a tumor. B, 
Comparison of the two most distinct 
mutation types observed in As-LUSC 
tumor (labeled in red on the x axis) 
with the 171 LUSC. Only 86 of the 
171 TCGA LUSCs were labeled on the 
figure because of space constraints. 
C, Fraction of T>G/A>C and C>A/
G>T transversions between As-LUSC 
and other LUSC. Black horizontal 
lines in groups represent median and 
minimum and maximum values. NS, 
never smoker; FS, former smoker; 
CS, current smoker; LUSC, lung 
squamous-cell carcinoma; As-LUSC, 
arsenic-related LUSC; TCGA, The 
Cancer Genome Atlas.
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is less than 5 × 10−6. Conversely, the fraction of C>A/G>T 
transversions in the As-LUSC (6.1%) was among the lowest 
of those observed across the 171 LUSC genomes examined 
(p value for permutation test = 0.0039; Fig. 3B).
We compared the As-LUSC with seven LUSC and 
tumors from lifelong never smokers, removing the mutations 
induced by tobacco smoke: The same distinctive mutational 
spectrum was observed relative to never-smoker tumors 
(Fig. 4A). The fraction of T>G/A>C transversions in the 
As-LUSC was the highest. Conversely, the proportion of 
C>A/G>T transversions was the lowest compared with that of 
never smokers (Fig. 4B).
As-LUSC Harbors a Somatic TP53 
Mutation Uncommon in Lung Cancer
To assess whether distinct mutation patterns existed at 
the gene level, we examined mutations affecting TP53 in the 
As-LUSC, as this gene is frequently mutated in lung cancer. 
One mutation (G>C), located at position 7,578,395 on chro-
mosome 17, was somatic. We confirmed this mutation by 
examining the RNA sequence of the corresponding transcript. 
This specific mutation (H179D) affects the DNA-binding 
domain of p53. The same mutation was observed in only 
one other lung tumor in the external panel (a current smoker, 
LUSC), and only four of 2421 lung tumors with mutations in 
TP53 harbored this exact change in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database.9
DISCUSSION
In North America and worldwide, it is estimated that 
150 million people are at increased risk of arsenic-related 
diseases including cancer. An improved understanding of 
arsenic-mediated tumorigenesis is urgently needed. Clinical 
and molecular data generated to date suggest arsenic- 
induced cancers may develop through molecular mecha-
nisms distinct from those of other carcinogens. Mutational 
signatures are often associated with specific mutagens; we 
hypothesized that an arsenic-related lung tumor would dis-
play a mutational profile distinct from histologically similar 
tumors unrelated to arsenic. We conducted the first WGS 
analysis of an arsenic-related human lung tumor, and found 
that indeed arsenic exposure is likely associated with a dis-
tinct mutational signature characterized by a low overall 
number of mutations, high rates of T>G/A>C, and low rates 
of C>A/G>T transversions.
The patient studied had lived in Antofagasta, Northern 
Chile, for 50 years, where the lung cancer mortality rate in 
people after exposure to arsenic is three- to fourfold greater 
than in unexposed individuals.5 Arsenic concentrations of the 
only drinking water source (Toconce river) for this city have 
FIGURE 4.  As-LUSC exhibits a different mutational profile compared with squamous lung tumors from never smokers. A, 
Comparison of T>G/A>C and C>A/G>T transversions between As-LUSC and seven LUSC from never smokers. B, Comparison of 
T>G/A>C and C>A/G>T transversions in As-LUSC and seven LUSC from never smokers (compared as individual groups). Black 
horizontal lines in groups represent median and min/max values. LUSC, lung squamous-cell carcinoma; As-LUSC, arsenic-related 
LUSC; TCGA, The Cancer Genome Atlas; NS, never smoker.
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been recorded since the 1950s, allowing estimation of past 
exposure among residents in this area.5 Additionally, molec-
ular evidence we discovered by WGS further corroborates 
chronic arsenic exposure of this patient. For example, very 
low levels of mutational load observed in arsenic studies—
attributed to arsenic’s lack of interaction with DNA10—was 
also strikingly observed in our As-LUSC.
Histological and molecular features of this case were 
consistent with squamous histology, however, the As-LUSC 
exhibited a highly distinctive pattern of somatic mutations, 
including a high proportion of T>G/A>C transversions, and 
a low fraction of C>A/G>T transversions. Interestingly, these 
mutations are reportedly some of the least frequent types 
of point mutations observed in non–small-cell lung cancer, 
where lung tumors from smokers are dominated by G>T/
C>A transversions, and never smokers with G>A/C>T transi-
tions.8,11 Given the low frequency of these mutations in other 
non–small-cell lung cancer, our results suggest that T>G/A>C 
transversions are likely associated with arsenic-induced lung 
cancer and may be used as a marker of arsenic exposure in the 
general population.
Different carcinogens are known to cause specific TP53 
mutations.12 The somatic mutation we detected in TP53 was 
a G>C transversion, which is an uncommon type of TP53 
mutation in lung cancer. Interestingly, G>C mutations in 
TP53 have been observed in arsenic-related skin and bladder 
tumors,13,14 and the frequency of these specific transversions 
is considerably higher under oxidative stress.15 In arsenic 
metabolism, arsenic induces 8-hydroxy-2-deoxyguanosine 
(8OHdG), which under specific oxidation conditions, is linked 
to the generation of G>C/C>G transversions.15 Because G>C/
C>G transversions are one of the most prominent types of 
point mutations affecting coding sequences in the As-LUSC, 
we postulate that specific events occurring during arsenic-
induced carcinogenesis in lung cells may be responsible for 
increasing G>C/C>G transversions in not only TP53, but also 
other genes important to lung cancer as well.
In conclusion, although we acknowledge that our study 
is limited by the analysis of a single As-LUSC, our whole-
genome sequence characterization provides novel evidence 
that a distinct mutational spectrum likely defines arsenic-
related lung cancer. Our results support the concept that arse-
nic induces lung cancers through mechanisms distinct from 
tobacco and other nonarsenic carcinogens; and that its sig-
nature mutational spectrum could be explored for its clinical 
utility in signifying cancers likely caused by arsenic exposure. 
Further study into the mutational profiles of other arsenic-
related cancers is warranted. These data may yield valuable 
insight into critically needed diagnostic and therapeutic tar-
gets for the growing population of people chronically exposed 
to arsenic-contaminated drinking water worldwide.
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